JP2005525403A - エストラジオール代謝産物の徐放性組成物 - Google Patents

エストラジオール代謝産物の徐放性組成物 Download PDF

Info

Publication number
JP2005525403A
JP2005525403A JP2004500770A JP2004500770A JP2005525403A JP 2005525403 A JP2005525403 A JP 2005525403A JP 2004500770 A JP2004500770 A JP 2004500770A JP 2004500770 A JP2004500770 A JP 2004500770A JP 2005525403 A JP2005525403 A JP 2005525403A
Authority
JP
Japan
Prior art keywords
hydroxyestradiol
composition
poly
methoxyestradiol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004500770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525403A5 (enExample
Inventor
ディーン エス． アリソン，
ポウル ジー． シュミット，
ポウル エス． ハドナット，
Original Assignee
ピーアール ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーアール ファーマシューティカルズ， インコーポレイテッド filed Critical ピーアール ファーマシューティカルズ， インコーポレイテッド
Publication of JP2005525403A publication Critical patent/JP2005525403A/ja
Publication of JP2005525403A5 publication Critical patent/JP2005525403A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
JP2004500770A 2002-05-03 2003-04-25 エストラジオール代謝産物の徐放性組成物 Pending JP2005525403A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37749002P 2002-05-03 2002-05-03
PCT/US2003/012727 WO2003092585A2 (en) 2002-05-02 2003-04-25 Controlled release compositions of estradiol metabolites

Publications (2)

Publication Number Publication Date
JP2005525403A true JP2005525403A (ja) 2005-08-25
JP2005525403A5 JP2005525403A5 (enExample) 2006-06-08

Family

ID=29401508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004500770A Pending JP2005525403A (ja) 2002-05-03 2003-04-25 エストラジオール代謝産物の徐放性組成物

Country Status (7)

Country Link
US (1) US20060083778A1 (enExample)
EP (1) EP1507514B1 (enExample)
JP (1) JP2005525403A (enExample)
AT (1) ATE353632T1 (enExample)
AU (1) AU2003231082A1 (enExample)
DE (1) DE60311801T2 (enExample)
WO (1) WO2003092585A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528179A (ja) * 2003-07-23 2006-12-14 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
JP2010528981A (ja) * 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
JP2013513610A (ja) * 2009-12-11 2013-04-22 バイオリテック ファーマ マーケティング リミテッド 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム
KR20140063964A (ko) * 2012-11-19 2014-05-28 가톨릭대학교 산학협력단 세포배양용 다공성 지지체 및 이의 제조방법
WO2020189886A3 (ko) * 2019-03-19 2021-04-22 (주)리젠바이오텍 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157816A1 (en) * 2002-08-26 2004-08-12 Girouard Michael P. Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents
EP1829529A1 (en) * 2002-05-03 2007-09-05 PR Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
US20040082558A1 (en) * 2002-08-02 2004-04-29 Tofovic Stevan P. Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity
JP2007515392A (ja) 2003-04-10 2007-06-14 ピーアール ファーマシューティカルズ，インコーポレイテッド エマルジョンベースの微粒子の製造のための方法
ES2625343T3 (es) 2003-07-15 2017-07-19 Evonik Corporation Método para la preparación de formulaciones de liberación controlada
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
CN101115471B (zh) * 2005-02-17 2011-02-09 梅迪沃什有限公司 聚合物颗粒输送组合物及使用方法
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP2091516A2 (en) 2006-12-01 2009-08-26 Anterios, Inc. Peptide nanoparticles and uses therefor
KR20150028856A (ko) 2007-05-31 2015-03-16 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
EP2196194B1 (en) * 2007-09-10 2017-08-09 M Technique Co., Ltd. Process for producing biological ingesta and biological ingesta obtained thereby
US20120015017A1 (en) * 2009-05-19 2012-01-19 Nyden Bo Magnus Slow releasing microcapsules containing an active substance
CN101953774B (zh) * 2010-09-17 2011-11-23 郑州大学 2-甲氧基雌二醇可注射水凝胶植入剂
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10227369B2 (en) 2013-03-12 2019-03-12 The Johns Hopkins University Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications
GB2521334B (en) * 2013-08-21 2018-06-20 Univ Swansea Topical drug patch including microspheres
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
CL2013003807A1 (es) * 2013-12-31 2014-07-11 Univ Santiago Chile Dispositivos de tubos pequeños de silicona que contienen nanopartículas y micropartículas de zeolitas como agentes de liberación prolongada y controlada, cargadas con 2-metoxiestradiol y suspendidas en un medio oleoso que también contiene 2-metoxiestradiol.
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3277241B1 (en) 2015-03-31 2023-12-20 Merck Sharp & Dohme B.V. Vaginal ring applicator
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
CN113509448A (zh) * 2020-07-02 2021-10-19 安徽中医药大学 一种可生物降解控释长效植入片及其制备方法
CN116059181A (zh) * 2022-09-26 2023-05-05 上海交通大学医学院附属新华医院 一种纳米药物递送系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027132A1 (en) * 1999-10-14 2001-04-19 The University Of Melbourne Estradiol conjugates and uses thereof
JP2005501096A (ja) * 2001-08-17 2005-01-13 ユニヴァーシティ オブ ピッツバーグ 肥満、代謝症候群、糖尿病、血管障害及び腎臓疾患を治療又は予防するエストラジオールメタボライトの投与

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5643595A (en) * 1992-11-24 1997-07-01 Alkermes Controlled Therapeutics Inc. Ii Growth promoters for animals
CN1156961A (zh) * 1995-06-09 1997-08-13 欧罗赛铁克股份有限公司 产生长效局部麻醉的制剂和方法
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
WO1998046212A1 (en) * 1997-04-17 1998-10-22 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027132A1 (en) * 1999-10-14 2001-04-19 The University Of Melbourne Estradiol conjugates and uses thereof
JP2005501096A (ja) * 2001-08-17 2005-01-13 ユニヴァーシティ オブ ピッツバーグ 肥満、代謝症候群、糖尿病、血管障害及び腎臓疾患を治療又は予防するエストラジオールメタボライトの投与

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528179A (ja) * 2003-07-23 2006-12-14 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
JP2010528981A (ja) * 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
JP2013513610A (ja) * 2009-12-11 2013-04-22 バイオリテック ファーマ マーケティング リミテッド 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム
KR20140063964A (ko) * 2012-11-19 2014-05-28 가톨릭대학교 산학협력단 세포배양용 다공성 지지체 및 이의 제조방법
KR102005579B1 (ko) 2012-11-19 2019-07-30 가톨릭대학교 산학협력단 세포배양용 다공성 지지체 및 이의 제조방법
WO2020189886A3 (ko) * 2019-03-19 2021-04-22 (주)리젠바이오텍 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법
JP2022525705A (ja) * 2019-03-19 2022-05-18 株式会社リーゼンバイオテク ステロイド系薬物を含む生分解性高分子微細粒子及びその製造方法
US11376226B2 (en) 2019-03-19 2022-07-05 Regenbiotech, Inc. Biodegradable polymer microparticle containing steroid drug and preparation method therefor
JP7296520B2 (ja) 2019-03-19 2023-06-22 株式会社リーゼンバイオテク ステロイド系薬物を含む生分解性高分子微細粒子及びその製造方法

Also Published As

Publication number Publication date
AU2003231082A8 (en) 2003-11-17
EP1507514A4 (en) 2005-08-10
DE60311801T2 (de) 2007-11-08
WO2003092585A2 (en) 2003-11-13
US20060083778A1 (en) 2006-04-20
EP1507514A2 (en) 2005-02-23
ATE353632T1 (de) 2007-03-15
EP1507514B1 (en) 2007-02-14
DE60311801D1 (de) 2007-03-29
WO2003092585A3 (en) 2004-08-19
AU2003231082A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
EP1507514B1 (en) Controlled release compositions of estradiol metabolites
Song et al. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery
Reithmeier et al. Development and characterization of lipid microparticles as a drug carrier for somatostatin
JP5153032B2 (ja) 薬物送達において使用するための、ポリマーおよび疎水性化合物で形成されるマトリックス
EP1343480B2 (en) Induced phase transition method for the production of microparticles containing hydrophobic active agents
JPH11511763A (ja) 安全な局所麻酔の提供方法
JP2010505821A (ja) デポ型注射剤組成物とその調製方法
Slager et al. Stereocomplexes based on poly (lactic acid) and insulin: formulation and release studies
US8663677B2 (en) Controlled release system and manufacturing method thereof
US7087246B2 (en) Controlled release preparation of insulin and its method
Graves et al. Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules
JP2013503113A (ja) フルベストラントナノスフェア／ミクロスフェア並びにその調製方法及び使用
JP2012193212A (ja) 優れた初期放出抑制特性を有する徐放性マイクロカプセルの製造方法及びこれにより製造されるマイクロカプセル
CA3164597A1 (en) Cariprazine release formulations
WO1999012571A1 (en) Nanocapsule preparations for treating intraarticular diseases
WO2018108164A1 (zh) 一种硼替佐米药物组合物及其应用
WO2018108163A1 (zh) 一种Talazoparib药物组合物及其应用
KR101663560B1 (ko) 균일한 서방출성 미립구의 제조방법
CN101264058B (zh) 石杉碱甲及其衍生物或其盐的缓释纳米粒、和它的制造方法
CN102370630A (zh) 重组人生长激素rhGH长效缓释微囊及其制备方法
CN101612111B (zh) 醋酸诺美孕酮或其类似物的缓释微球及其制备方法和用途
US11110061B2 (en) Microspherical sustained-release injection containing escitalopram and method for preparing same
Sheikh Injectable controlled release drug delivery systems
CN120267621A (zh) 一种多奈哌齐缓释制剂及其制备方法
EP1829529A1 (en) Controlled release compositions of estradiol metabolites

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100420